A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China

Liu, Jinsong; Hou, Xiaohua

doi:10.1111/j.1440-1746.2011.06641.x

Cited by 50 publications

(35 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is slightly lower than the report of a prevalence of irritable bowel symptoms of 30% in Northern Sweden [6], yet higher than most reports on the prevalence of IBS: A European telephone survey of more than 40,000 subjects found a prevalence of IBS of 11.5% [37], and a Norwegian study reported a prevalence of 8.4% [38]. Reviews of this field mostly report an IBS prevalence of 10-15% [39][40][41] in the West, and a lower prevalence in China and other Eastern Asian countries [42]. IBS prevalence estimates also vary with the criteria used for diagnosis [43].…”

Section: Discussionmentioning

confidence: 94%

Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway

Breckan

Asfeldt

Straume

et al. 2012

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway

Breckan

Asfeldt

Straume

et al. 2012

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Most of the included studies were retrospective (36 articles). Among the included studies, six were from India, 12–17 four from Korea, 18–21 seven from Japan, 22–28 eight from China, 29–36 three each from Taiwan, 37–39 Singapore, 40–42 Malaysia, 43–45 and Israel, 46–48 two from Turkey, 49,50 and one each from Kuwait, 51 Sri Lanka, 52 Jordan, 53 Iran, 54 and Oman. 55 Six studies reported colorectal cancer risk in patients undergoing routine surveillance.…”

Section: Resultsmentioning

confidence: 99%

Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis

Bopanna

Ananthakrishnan

Kedia

et al. 2017

The Lancet Gastroenterology & Hepatology

171

104

View full text Add to dashboard Cite

Summary Background The increased risk of colorectal cancer in ulcerative colitis is well known. The risk of sporadic colorectal cancer in Asian populations is considered low and risk estimates of colorectal cancer related to ulcerative colitis from Asia vary. This meta-analysis is an Asian perspective on the risk of colorectal cancer related to ulcerative colitis. Methods We searched PubMed and Embase for terms related to colorectal cancer in ulcerative colitis from inception to July 1, 2016. The search for published articles was done by country for all countries in Asia. We included studies with information on the prevalence and cumulative risk of colorectal cancer at various timepoints. A random-effects meta-analysis was done to calculate the pooled prevalence as well as a cumulative risk at 10 years, 20 years, and 30 years of disease. Findings Our search identified 2575 articles; of which 44 were eligible for inclusion. Our analysis included a total of 31 287 patients with ulcerative colitis with a total of 293 reported colorectal cancers. Using pooled prevalence estimates from various studies, the overall prevalence was 0·85% (95% CI 0·65–1·04). The risks for colorectal cancer were 0·02% (95% CI 0·00–0·04) at 10 years, 4·81% (3·26–6·36) at 20 years, and 13·91% (7·09–20·72) at 30 years. Subgroup analysis by stratifying the studies according to region or period of the study did not reveal any significant differences. Interpretation We found the risk of colorectal cancer in Asian patients with ulcerative colitis was similar to recent estimates in Europe and North America. Adherence to screening is therefore necessary. Larger population-based, prospective studies are required for better estimates of the risk.

show abstract

“…Prevalence estimates for IBS appear to vary widely according to the criteria used and population studied[3]. The reported prevalence of IBS in Western countries ranges from 17%-22%[4]; but a highly variable range between 2.3%-34% is reported in Asian countries[5,6]. In China, most studies applying the Rome II criteria reported the IBS prevalence in adult as between 5% to 10%[7].…”

Section: Introductionmentioning

confidence: 99%

Economic burden of irritable bowel syndrome in China

Zhang

Xiang

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo estimate annual direct and indirect costs for patients diagnosed with irritable bowel syndrome (IBS) and subtypes.METHODSPatients completed a standardized questionnaire concerning usage of healthcare resources, travel costs, meals, and productivity loss of patients when seeking treatment for IBS. Total annual costs per patient were calculated as the sum of direct (including medical and nonmedical) and indirect costs. Total annual costs per patient among various IBS subtypes were compared. Analysis of variance and bootstrapped independent sample t-tests were performed to determine differences between groups after controlling for IBS subtypes.RESULTSA total of 105 IBS patients (64.80% female), mean age of 57.12 years ± 10.31 years), mean disease duration of 4.31 years ± 5.40 years, were included. Total annual costs per patient were estimated as CNY18262.84 (USD2933.08). Inpatient and outpatient healthcare use were major cost drivers, accounting for 46.41%and 23.36% of total annual costs, respectively. Productivity loss accounted for 25.32% of total annual costs. The proportions of direct and indirect costs were similar to published studies in other countries. Nationally, the total costs of managing IBS would amount to CNY123.83 billion (USD1.99 billion). Among the IBS subtypes, total annual costs per patient of IBS-M was highest at CNY18891.18 (USD3034). Furthermore, there was significant difference in productivity loss among IBS subtypes (P = 0.031).CONCLUSIONIBS imposes a huge economic burden on patients and healthcare systems, which could account for 3.3% of the total healthcare budget for the entire Chinese nation. More than two-thirds of total annual costs of IBS consist of inpatient and outpatient healthcare use. Among the subtypes, IBS-M patients appear to have the greatest economic burden but require further confirmation.

show abstract

A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China

Cited by 50 publications

References 10 publications

Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway

Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway

Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis

Economic burden of irritable bowel syndrome in China

Contact Info

Product

Resources

About